tirzepatide for metabolic dysfunction Frontiers A summary of the beneficial

Spezani R, Silva RR, Martins FF, Marinho TS, Aguila MB, Mandarim-de-Lacerda CA

Cannot redeclare control with same name "grid_6_qv_dots_heading"

Although evidence from clinical trials has shown GLP-1 RAs to be safe and efficacious in people living with T2DM and renal impairment, their use is uncommon in this patient population

Each batch is crafted with an unflinching focus on achieving the exact amino-acid sequence

Hence, we propose that peptides/peptidomimetics could compensate the FMRP deficiency restoring the imbalance of protein synthesis and actin dynamics, suggesting a new and promising strategy for treating FXS

(2023) 19:e1011090